Get a clear picture of Alzheimer’s disease pathology.

Leverage a single test that has high concordance with amyloid PET status1


Remove diagnostic testing barriers with a simple blood draw

Gain accurate insights with a clinically-validated algorithm that combines Aβ42/40 and p-tau217/np-tau217 (%p-tau217) ratios

Get clear answers with Positive or Negative results that reflect high or low likelihood for the presence of brain amyloid pathology

Powerful performance.

Proven performance of the PrecivityAD2™ test derives from the clinically-validated algorithm using a single cutoff that combines both the Aβ42/40 ratio and the p-tau217/np-tau217 ratio (%p-tau217) to help give you accurate insights into your patient's condition with a convenient blood draw.1


  • 88% sensitivity

  • 89% specificity

  • 0.94 AUC-ROC

1. Meyer MR, Kirmess KM, Eastwood S, et al. Clinical validation of the PrecivityAD2TM blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. Published online March 16, 2024. doi:10.1002/alz.13764. The PrecivityAD2TM blood test is intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia, who are undergoing evaluation for Alzheimer's disease or other causes of cognitive decline.

Making testing more accessible to more patients.

As a healthcare provider, you now have multiple blood draw options for your patients. These convenient choices include:


Scheduling a draw at one of the patient service centers available nationwide


Using a mobile phlebotomy service to visit the patient's home


Facilitating blood draws in office with your phlebotomist


Clinical validation of the
PrecivityAD2™ blood test

Get in touch

If you are a healthcare provider interested in ordering a PrecivityAD2™ test or have a question, complete the form and a C₂N Diagnostics staff member will be in touch soon.